All posts by : Felistas

Paxlovid does not significantly reduce COVID-19 hospitalization and mortality among vaccinated older adults, according to new UCLA-led research.

Scientists at the Icahn School of Medicine at Mount Sinai and collaborators have identified novel genetic interactions that may contribute to congenital heart disease (CHD), a common birth defect.

Building on more than two decades of research, a study by MIT neuroscientists at The Picower Institute for Learning and Memory reports a new way to treat pathology and symptoms of fragile X syndrome, the most common genetically-caused autism spectrum disorder. The team showed that augmenting a novel type of neurotransmitter signaling reduced hallmarks of fragile X in mouse models of the disorder.

In their effort to answer a decades-old biological question about how the hepatitis B virus (HBV) is able to establish infection of liver cells, research led by Memorial Sloan Kettering Cancer Center (MSK), Weill Cornell Medicine, and The Rockefeller University identified a vulnerability that opens the door to new treatments.

A multimodal, digital community-based intervention was feasible and decreased illness-related distress in treating patients with chronic obstructive pulmonary disease (COPD), according to a study led by UMass Chan Medical School Program in Digital Medicine researchers.

An inhalable medicine with the potential to improve lung disease in people with cystic fibrosis, irrespective of their mutation type, is being tested in human trials in the UK and Europe.

Spinal muscular atrophy (SMA) is a progressive neurodegenerative disorder set in motion before birth. Scientists at St. Jude Children’s Research Hospital led the first in utero treatment of SMA with the orally administered drug risdiplam.

Genetic testing should be used to help doctors spot high-risk cases of myeloma and enable targeted treatments, say researchers from the University of Leeds and The Institute of Cancer Research.

A new vaccine that boosts immunity against tuberculosis (TB) has been shown to be effective in pioneering pre-clinical trials, as part of a successful collaboration between three leading Australian research institutions.

Each month, Michelle Shaw went to a pain clinic to get the shots that made her back feel worse—so she could get the pills that made her back feel better.